Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Primary Objective
To evaluate the 3-month event-free survival of the combination of the combination of
itraconazole and pemetrexed in patients with recurrent/refractory non-small cell lung cancer.
Secondary Objectives
To determine the objective response rate of the combination of itraconazole and pemetrexed in
patients with recurrent/refractory non-small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins